Inclusion Criteria:
1. Ability to understand study requirements, follow study instructions and to return for required study follow-up visits as confirmed by provision of written informed consent.
2. Participant has undergone cataract surgery with an implantation of mono focal IOL.
3. Participant has no significant residual visual issues which the Investigator believes would make the patient ill-suited for the treatment.
4. Vision must be clinically stable in the Investigator's judgment.
5. Each eye has Corrected Distance Visual Acuity (CDVA) of at least 0.2 logMAR (20/32).
Specific inclusion criteria for Cohort 1: Creating near vision (participants must fulfill all criteria to be enrolled in Cohort 1).
1. Participant has a mono focal intraocular lens implanted in both eyes.
2. Both eyes have uncorrected distance visual acuity (UDVA) of 20/40 (0.3 logMAR) or better at 4 meters.
3. Each eye has near vision assessed as Distance Corrected Near Visual Acuity (DCNVA) worse than Jeager 8 and/or ETDRS 0.5 logMAR.
Specific inclusion criteria for Cohort 2: Refractive correction (participants must fulfill all criteria to be enrolled in Cohort 2).
1. Participant has a mono focal intraocular lens implanted in one or both eyes.
2. The eye to be treated requires an adjustment of at least 1.0 D in sphere or cylinder.
3. Difference between UDVA and CDVA pre-treatment is at least 2 lines i.e. 0.2 logMAR.
Exclusion Criteria:
1. Participants not able to complete the informed consent form.
2. Clinically significant corneal abnormalities including corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy), inflammation, keratitis, keratoconjunctivitis, keratouveitis, keratopathy, keratectasia or edema per the Investigator's expert medical opinion.
3. Previous corneal surgery.
4. Previous refractive surgery or proposed refractive surgery procedures throughout the entire duration of the participants' participation in the clinical study (including, but not limited to LASIK, astigmatic keratotomy and limbal relaxing incisions).
5. History of or current retinal conditions or predisposition to retinal conditions including retinal detachment, diabetic retinopathy, age related macular degeneration which are assessed to by Investigator to confound outcomes.
6. Amblyopia.
7. History of or current anterior or posterior segment inflammation of any etiology, or any disease producing an inflammatory reaction in the eye (e.g., iritis or uveitis).
8. Optic nerve atrophy.
9. Iris neovascularization.
10. Participants with diagnosed degenerative eye disorders (e.g., macular degeneration or other retinal disorders).
11. Uncontrolled glaucoma.
12. Any participant currently participating in any other investigational drug or device studies.
13. Participants unable to reliably perform visual acuity testing or defocus curve assessments, including intolerance to trial frame correction or inconsistent test responses, in the opinion of the Investigator.
14. Clinically significant posterior capsule opacification (PCO) in the study eye that, in the Investigator's judgment, could affect visual acuity, contrast sensitivity, or confound study outcomes.
15. Any participant disqualified by the Principal Investigator or Medical Monitor for any ocular issue.
